NOTICE: Investors in NRx Pharmaceuticals, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – NRXP; NRXPW
SAN DIEGO--(BUSINESS WIRE)--#NRXPWstock--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”) have until March 21, 2022 to seek appointment as lead plaintiff in Dal Bosco v. NRx…
Read More...
